European Commission claims pharma competition success

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

European Commission claims pharma competition success

The proportion of problematic patent settlements in the pharmaceutical industry has fallen, even though the number of settlements has grown, according to the European Commission

In a statement published on January 31, the Commission said that its third annual survey had found that 11% of antitrust settlements were potentially problematic from an antitrust point of view, compared to 21% when the pharmaceutical sector enquiry was conducted in 2008 to 2009.

That came as the total number of settlements reached 120 in 2011, compared to 24 at the time of the enquiry. “This shows that the Commission's action has not hindered companies from concluding settlements, contrary to fears expressed by certain stakeholders in that respect. At the same time the monitoring exercises may have generally increased stakeholders' awareness of competition law issues, given the lower number of potentially problematic settlements,” said the statement.

The Commission also revealed that it has initiated a third investigation regarding possible competition abuse. The latest case involves the drug Fentanyl, said the Commission: “Rather than competing, the companies entered here into a so-called co-promotion agreement resulting in consumers being deprived of access to a cheaper pain killer medicine. The co-promotion agreement foresaw monthly payments from J&J to its close generic competitor for as long as no generic product was launched in the Dutch market. Consequently, Sandoz abstained from entering the market with generic fentanyl patches for the duration of the agreement. This behaviour, if established, would infringe Article 101 TFEU.”

The two other investigations, which are continuing, involve agreements between Lundbeck and various generic companies concerning the drug Citalopram and between Servier and several generic companies regarding the drug Perindopril.

The Commission can fine companies where it finds evidence of competition abuse. The Court of Justice of the EU recently upheld a finding that AstraZeneca had acted to prevent or delay the entry of generic products.

more from across site and SHARED ros bottom lb

More from across our site

Attorneys explain why there are early signs that the US Supreme Court could rule in favour of ISP Cox in a copyright dispute
A swathe of UPC-related hires suggests firms are taking the forum seriously, as questions over the transitional stage begin
A win for Nintendo in China and King & Spalding hiring a prominent patent litigator were also among the top talking points
Rebecca Newman at Addleshaw Goddard, who live-reported on the seminal dispute, unpicks the trials and tribulations of the case and considers its impact
Attorneys predict how Lululemon’s trade dress and design patent suit against Costco could play out
Lawyers at Linklaters analyse some of the key UPC trends so far, and look ahead to life beyond the transition period
David Rodrigues, who previously worked at an IP boutique, said he may become more involved in transactional work at his new firm
Indian smartphone maker Lava must pay $2.3 million as a security deposit for past sales, as its dispute with Dolby over audio coding SEPs plays out
Powell Gilbert’s opening in Düsseldorf, complete with a new partner hire, continues this summer’s trend of UPC-related lateral movement
IP leaders at Brandsmiths and Bird & Bird, who were on opposing sides at the UK Supreme Court in Iconix v Dream Pairs, unpick the landmark case and its ramifications
Gift this article